Revenue
2009
2010
2011
2012
2013
2014
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
Harvard Bioscience Inc (HBIO)
Price$8.28Cached quote
Net income
2009
2010
2011
2012
2013
2014
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
Free cash flow
2017
2018
2019
2020
2021
2022
2023
2024
2025
Total cash / debt
CashTotal debt
2009
2010
2011
2012
2013
2014
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
Financial statements
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $86.5M | $94.1M | $112.3M | $113.3M | $118.9M | $102.1M | $116.2M | $120.8M | $77.4M | $104.5M | $108.7M | $108.7M | $105.2M | $111.2M | $108.9M | $108.2M | $85.8M |
| Gross profit | $49.9M | $54.8M | $66.1M | $60.8M | $67.7M | $58.0M | $64.3M | $63.2M | $39.2M | $48.4M | $48.7M | $49.3M | $47.7M | $52.3M | $50.2M | $51.8M | $41.7M |
| Gross margin | 57.67% | 58.18% | 58.86% | 53.66% | 56.90% | 56.85% | 55.37% | 52.31% | 50.60% | 46.32% | 44.84% | 45.41% | 45.35% | 47.08% | 46.11% | 47.89% | 48.60% |
| Research & development | $8.8M | $10.4M | $11.8M | $12.3M | $10.8M | $8.7M | $10.7M | $11.0M | $5.6M | $5.4M | $6.4M | $4.9M | $4.2M | $4.3M | $3.9M | $4.7M | $4.4M |
| Operating expenses | $98.5M | $61.0M | $64.2M | $67.8M | $65.6M | $57.8M | $63.9M | $62.2M | $39.8M | $51.4M | $50.4M | $42.7M | $46.2M | $44.5M | $41.8M | $41.6M | $33.6M |
| Operating income | −$48.6M | −$6.2M | $1.9M | −$6.9M | $2.1M | $221,000 | $377,000 | $984,000 | −$635,000 | −$3.0M | −$1.7M | $6.6M | $1.5M | $7.8M | $8.4M | $10.2M | $8.1M |
| Operating margin | −56.13% | −6.60% | 1.69% | −6.12% | 1.74% | 0.22% | 0.32% | 0.81% | −0.82% | −2.87% | −1.58% | 6.09% | 1.46% | 7.04% | 7.72% | 9.45% | 9.39% |
| EBITDA | −$42.8M | $771,000 | $8.9M | $642,000 | $9.7M | $7.9M | $8.1M | $8.8M | $2.2M | $1.3M | $2.9M | $10.4M | $5.4M | $12.0M | $12.7M | $14.1M | $11.1M |
| EBITDA margin | −49.46% | 0.82% | 7.92% | 0.57% | 8.15% | 7.69% | 6.98% | 7.28% | 2.89% | 1.20% | 2.62% | 9.62% | 5.16% | 10.83% | 11.70% | 13.07% | 12.94% |
| Net income | −$56.7M | −$12.4M | −$3.4M | −$9.5M | −$288,000 | −$7.8M | −$4.7M | −$2.9M | −$865,000 | −$4.3M | −$19.0M | $2.4M | −$1.8M | $2.4M | $3.8M | $19.0M | $7.2M |
| Net profit margin | −65.51% | −13.18% | −3.04% | −8.40% | −0.24% | −7.65% | −4.03% | −2.42% | −1.12% | −4.12% | −17.52% | 2.17% | −1.74% | 2.13% | 3.50% | 17.58% | 8.43% |
| Basic EPSper basic share | -$12.80 | -$2.80 | -$0.80 | -$2.30 | -$0.10 | -$2.00 | -$1.20 | -$0.80 | -$0.20 | -$1.30 | -$5.70 | $0.70 | -$0.60 | $0.90 | $1.40 | $6.60 | $2.40 |
| Diluted EPSper diluted share | -$12.80 | -$2.80 | -$0.80 | -$2.30 | -$0.10 | -$2.00 | -$1.20 | -$0.80 | -$0.20 | -$1.30 | -$5.70 | $0.70 | -$0.60 | $0.80 | $1.30 | $6.50 | $2.40 |
Owners
Reported shareholders
Reported holdings Number of shares
View holders
| Holder | Shares held |
|---|---|
Duke John D | 180K |
Cote Jennifer | 159.02K |
Eade Katherine A. | 58.67K |
Snider William | 48.56K |
Frost Mark T | 47.5K |
DENELSKY STEPHEN J | 37.56K |
Gagnon Robert E. | 27.56K |
Benson Seth Benjamin | 27.56K |
Green James W | — |
Bars compare reported share counts. A matching total for this share class and reporting period is unavailable, so percentages are not shown.
Source: SEC Form 4 ↗Updated Sep 29, 2026 · Quarterly data
Insider buys & sells
| Transaction | Insider | Type | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| Mar 17, 2026Form 4 | DENELSKY STEPHEN JDirector | BuyCommon Stock | 10.0K | $4.87 | $48.7K | 21.0K |
| Mar 17, 2026Form 4 | Snider WilliamDirector | BuyCommon Stock | 8.5K | $4.85 | $41.1K | 32.0K |
| Mar 16, 2026Form 4 | Frost Mark TChief Financial Officer | BuyCommon Stock | 5.0K | $5.00 | $25.0K | 17.5K |
| Mar 16, 2026Form 4 | Snider WilliamDirector | BuyCommon Stock | 12.5K | $4.99 | $62.5K | 23.5K |
| Mar 16, 2026Form 4 | Duke John DChief Executive Officer | BuyCommon Stock | 5.0K | $5.01 | $25.1K | 105.0K |